JEOL Ltd. FY2027 Q1 Earnings Report

Quick View

Executive Summary

In Q1 of the fiscal year ending March 2027, JEOL posted a sharp decline in revenue and fell into an operating loss, reversing its previous growth trend. This was attributable to the decline in revenue following the transfer of the Medical Equipment Business and a rapid slowdown in demand. Revenue was ¥24.47B (-39.1% YoY), Operating Income was ¥-1.96B (-133.9% from ¥5.79B in the previous year), Ordinary Income was ¥-1.36B (-123.6%), and Net Income was ¥-1.71B (-136.6%). Although the gross margin was maintained at 48.1%, the company was unable to reduce SG&A expenses (¥13.73B, or 56.1% of revenue) flexibly enough to offset the sharp decline in revenue. The resulting increase in the burden of fixed costs was the primary cause of the operating loss.

Factors Affecting Performance

【Revenue】Revenue was ¥24.47B, representing a substantial 39.1% YoY decline. The primary factors were the exclusion of the Medical Equipment Business following its transfer and the slowdown in demand for the core Scientific and Measurement Instruments Business. By segment, the Scientific and Measurement Instruments Business generated revenue of ¥19.49B (79.7% of total revenue, YoY -8.8%), while the Industrial Equipment Business generated revenue of ¥4.98B (20.3%, YoY -65.6%). The decline in the Industrial Equipment Business was particularly significant.

【Profit and Loss】Operating Income fell into the red at ¥-1.96B, compared with ¥5.79B in the previous year. SG&A expense reductions were limited relative to the 39.1% decline in revenue, and insufficient fixed-cost absorption pressured profitability. Non-operating income of ¥0.72B (including dividend income of ¥0.15B, foreign exchange gains of ¥0.09B, and equity in earnings of affiliates of ¥0.20B, among others) partially offset the loss, limiting the Ordinary Loss to ¥-1.36B. Although the company recorded extraordinary income of ¥0.16B, primarily from gains on the sale of non-current assets, the burden of income taxes and other taxes of ¥0.51B caused the Net Loss to expand to ¥-1.71B. In conclusion, the company experienced both a decline in revenue and a decline in earnings.

Segment Analysis

Following the transfer of the Medical Equipment Business, the company’s segments were revised to two categories: the Scientific and Measurement Instruments Business and the Industrial Equipment Business. The Scientific and Measurement Instruments Business recorded revenue of ¥19.49B (79.7% of total revenue, YoY -8.8%) and an operating loss of ¥-0.27B, representing a 27.7% improvement in the loss from ¥-0.375B in the previous year and an operating margin of -1.4%. The Industrial Equipment Business recorded revenue of ¥4.98B (20.3% of total revenue, YoY -65.6%) and Operating Income of ¥0.22B, representing a substantial decline of 96.9% YoY from ¥7.18B and an operating margin of 4.4%, although it remained profitable. Corporate expense adjustments amounted to ¥-1.91B, which, when added to the combined operating result of ¥-0.05B from the two segments, resulted in a company-wide operating loss of ¥-1.96B. The Scientific and Measurement Instruments Business’s shift into the red and the sharp contraction in profits from the Industrial Equipment Business highlight structural issues in the company-wide portfolio.

Key Financial Metrics

【Profitability】The Operating Margin was -8.0% (14.4% in the previous year), while the Net Profit Margin was -7.0% (11.6% in the previous year), with both metrics showing substantial deterioration. The gross margin was maintained at 48.1%, indicating limited deterioration in pricing and product mix.【Cash Flow Quality】Accounts receivable declined 28.6% YoY to ¥36.08B, indicating progress in collections. However, inventories increased to ¥19.20B, including work in process of ¥5.60B, suggesting inventory and production-process stagnation. Contract liabilities increased to ¥34.84B, and the accumulation of advance payments could provide a source of future revenue recognition.【Investment Efficiency】ROE was -1.2%, primarily due to the deterioration in the Net Profit Margin and a decline in total asset turnover. R&D expenses remained at an aggressive level of ¥2.59B, or 10.6% of revenue.【Financial Soundness】The Equity Ratio improved to 62.3% (59.9% in the previous year). With cash and deposits of ¥32.24B and interest-bearing debt of approximately ¥11.5B, the company maintained a net cash position. Short-term borrowings were substantially reduced YoY, and the financial foundation remains conservative.

Cash Flow Analysis

Although direct disclosure of the statement of cash flows is limited in this earnings release, changes in the balance sheet provide insight into fund movements. Accounts receivable declined by ¥14.43B, from ¥50.50B to ¥36.08B, and collections of trade receivables contributed positively to cash flow despite the operating loss. Meanwhile, inventories increased from ¥17.15B to ¥19.20B. Work in process was particularly high at approximately ¥53.01B, potentially indicating production-process stagnation that is tying up cash. Contract liabilities increased from ¥29.77B to ¥34.84B, and the accumulation of advance payments supported liquidity. Short-term borrowings were substantially reduced from ¥14B to ¥4B, while cash and deposits were maintained at ¥32.24B, indicating that financial capacity remained intact despite the operating loss.

Quality of Earnings

The core business recorded an operating loss of ¥-1.96B, indicating a decline in recurring earnings power. Non-operating income of ¥0.72B (including dividend income of ¥0.15B, foreign exchange gains of ¥0.09B, and equity in earnings of affiliates of ¥0.20B, among others, equivalent to approximately 3.0% of revenue) partially offset the loss. Extraordinary income of ¥0.16B was primarily attributable to gains on the sale of non-current assets and was a temporary factor; its scale was not sufficient to materially change the Net Loss. The expansion from an Ordinary Loss of ¥-1.36B to a Net Loss of ¥-1.71B was primarily due to the burden of ¥0.51B in income taxes and other taxes despite the loss, which further reduced earnings. From an accrual perspective, inventories, particularly work in process, and contract liabilities increased simultaneously. This may indicate that the timing of revenue recognition has been pushed back, leaving a risk of divergence between earnings and cash flow until shipments and customer acceptance normalize.

Earnings Forecast and Guidance

Progress against the full-year plan was approximately 14.9%, based on revenue of ¥24.47B against ¥164.00B, remaining more than 10pt below the standard quarterly benchmark of 25%. Operating Income, Ordinary Income, and Net Income were all negative as of Q1, leaving a substantial shortfall against the full-year plan of Operating Income of ¥26.50B (+1.9% YoY) and Ordinary Income of ¥26.20B (-8.4% YoY). No revisions were made to either the earnings forecast or the dividend forecast, and management is maintaining its plan based on a recovery in the second half of the fiscal year. Achieving the plan will require accelerated shipments and customer acceptance from Q2 onward, as well as the resolution of production-process bottlenecks.

Shareholder Returns

The full-year dividend forecast is ¥132, and the Payout Ratio based on the full-year EPS forecast of ¥432.64 is approximately 30.5%. As of Q1, no revision had been made to the dividend forecast. Even with a Net Loss in Q1, cash and deposits of ¥32.24B and conservative financial leverage are supporting factors for the dividend. There is no disclosure regarding share buybacks, and shareholder returns are evaluated solely on the basis of dividends.

Risk Factors

1. Segment concentration risk: The Scientific and Measurement Instruments Business accounts for 79.7% of revenue and recorded an operating loss of ¥-0.27B. Accordingly, fluctuations in supply and demand in this segment have a direct impact on company-wide performance.

2. Risk of inventory and work-in-process stagnation: Inventories increased to ¥19.20B, with work in process accounting for more than half of the total. While collections of accounts receivable are progressing, production-process stagnation is suggested, potentially leading to risks of inventory write-downs and delivery delays.

3. Risk of failing to achieve guidance: Revenue progress was approximately 14.9%, substantially below the quarterly benchmark of 25%. Achieving the full-year plan of Operating Income of ¥26.50B and Ordinary Income of ¥26.20B will require a rapid acceleration in shipments from Q2 onward.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

The company’s profitability is substantially below the industry median and ranks toward the lower end of the industry.

Growth and Capital Efficiency

Revenue growth was also substantially below the industry median, placing the company in the lowest range within the industry for the quarter.

※Source: Compiled by the Company

Key Points from the Earnings Release

1. During the quarter, the segment revision resulting from the business transfer coincided with a slowdown in demand, causing substantial deterioration in both revenue and earnings from the previous year. In particular, the Scientific and Measurement Instruments Business’s shift into the red and the sharp decline in profits from the Industrial Equipment Business represent turning points in the company-wide earnings structure.

2. Inventories, particularly work in process, and contract liabilities increased simultaneously. While the accumulation of orders and advance payments indicates potential for future revenue recognition, deterioration in cash conversion may continue until production-process stagnation is resolved.

3. The financial foundation remains conservative, as evidenced by an Equity Ratio of 62.3% and the maintenance of a net cash position. The company is also reducing short-term borrowings despite the operating loss, and its financial resilience provides a buffer against downside risks to performance.

Theoretical Share Price (Reference Value)

Sensitivity: ¥3,395–¥3,599 at ±1% for the cost of equity, and ¥3,480–¥3,518 at ±0.1 for ω.

Notes:

• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit five-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, nor does it predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, and after consulting with a professional as necessary.

---End of Report---